Clinical trials: Solid Tumour
Cancer
Phase I Clinical Study of E7389
The primary objective of this study is to determine the dose limiting toxicity and maximum tolerated dose of E7389 in patients with solid tumors.
- Trial name
- NCT00326950
- Testing
- E7389
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Eisai Co., Ltd.
Neoplastic Meningitis
Depocyt® With Sorafenib in Neoplastic Meningitis
The purpose of this study is to determine the tolerability and side effects of oral sorafenib in combination with intrathecal DepoCyt.
- Trial name
- NCT00964743
- Testing
- DepoCyt, Sorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
S0916, MLN1202 in Treating Patients With Bone Metastases
RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01015560
- Testing
- anti-CCR2 monoclonal antibody MLN1202, polymorphism analysis, laboratory biomarker analysis
- Where
- 47 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and…
- Trial name
- NCT06242691
- Testing
- MK-1200, Antiemetic
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
- Trial name
- NCT03110107
- Testing
- Ipilimumab, BMS-986218, Nivolumab
- Where
- 52 sites in United States, Argentina and 15 more
- Volunteers
- 376 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
- Trial name
- NCT02718911
- Testing
- LY3022855, Durvalumab, Tremelimumab
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumours
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
This is a phase Ib, open-label, multicentre study of AZD1775 administered orally in monotherapy and in combination with carboplatin and paclitaxel to Asian patients with advanced solid tumours.
- Trial name
- NCT02341456
- Testing
- AZD1775, Paclitaxel, carboplatin
- Where
- 7 sites in Australia, Japan and 1 more
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
This Phase I/Il studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy work in treating patients with lung cancer that has spread to nearby tissues or lymph nodes.
- Conditions
- Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03735095
- Testing
- Porfimer Sodium, Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Neoplasms, Malignant Carcinoma
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
The primary purpose of this study is to identify the maximum tolerated dose(s) (MTD) of neratinib in combination with temsirolimus in subjects with solid tumors.
- Trial name
- NCT00838539
- Testing
- Neratinib, Temsirolimus
- Where
- 5 sites in United States, France
- Volunteers
- 63 people
- Sponsor
- Puma Biotechnology, Inc.
Non Small Cell Lung Cancer
A Study in Non Small Cell Lung Cancer
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer.
- Trial name
- NCT01139775
- Testing
- Pemetrexed, Cisplatin, LY2603618
- Where
- 24 sites in Germany, Spain
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390429
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of California, Davis
Advanced Solid Tumor Malignancy
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors in monotherapy and in combination with anti programmed cell…
- Trial name
- CICILIA (NCT04260529)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 8 sites in France, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Cytovation AS
Locally Advanced Solid Tumor
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of…
- Trial name
- NCT04084366
- Testing
- OBI-999
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- OBI Pharma, Inc
Solid Tumor, Adult
DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours
This is a Phase 1, multicentre, open-label, dose-escalation study to determine a recommended phase 2 dose (RP2D) of DT-9081, followed by an expansion study of DT-9081 in participants with advanced, recurrent or metastatic solid…
- Trial name
- EPRAD (NCT05582850)
- Testing
- DT-9081 - dose escalation, DT-9081 - expansion
- Where
- 4 sites in Belgium, France
- Volunteers
- 29 people
- Sponsor
- Domain Therapeutics SA
Advanced Solid Tumors, Neoplasms
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.
- Trial name
- NCT00207090
- Testing
- ixabepilone, Rifampin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- R-Pharm
Solid Tumors
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
- Trial name
- NCT01447225
- Testing
- MM-121, Carboplatin, Pemetrexed
- Where
- 5 sites in United States, France
- Volunteers
- 43 people
- Sponsor
- Merrimack Pharmaceuticals
Neoplasms
Phase I Trial of BI 836845 for Various Solid Cancer
This study is a phase I, open-label, dose escalation trial to determine the maximum tolerated dose (MTD) or the relevant biological dose (RBD) in the absence if a MTD of a new drug BI 836845 which blocks the insulin-like growth…
- Trial name
- NCT01403974
- Testing
- BI 836845
- Where
- 3 sites in Taiwan
- Volunteers
- 61 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor
A Study of EMD525797 in Solid Tumor Patients in Japan
The primary objectives are to assess the safety and tolerability of single and repeated doses of EMD525797, and characterize Pharmacokinetics (PK).
- Trial name
- NCT01327313
- Testing
- EMD525797
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer, Breast Cancer Stage IV
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations.
- Conditions
- Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma
- Trial name
- NCT05054374
- Testing
- Mirdametinib, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.